Amgenvs.Biogen
AMGN vs BIIB · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 7.0× larger than Biogen by market cap; Amgen trades at the lower P/E (25.5 vs 38.4); year to date, Biogen leads (+26.2% vs +23.0%).
Side by side
| AMGN | BIIB | |
|---|---|---|
| Market cap | $223B | $32.1B |
| Price | $407.44 | $218.43 |
| Today | −1.4% | −1.7% |
| Return YTD | +23.0% | +26.2% |
| Return 1Y | +36.9% | +45.9% |
| Since June 26, 2026 | +13.7% | +1.1% |
| P/E | 25.5 | 38.4 |
| P/S | 5.9 | 3.2 |
| P/B | 19.1 | 1.7 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →More AMGN & BIIB comparisons
Other head-to-heads in the Biotech & innovation segment.